Connect with us

Technologies

Ivermectin and COVID-19: Why poison centers are getting calls about this controversial drug

Is this a miracle pill or a sham?

Since the start of the COVID-19 pandemic, some medical professionals have reviewed already available drugs to see if they could be used as effective treatments. Ivermectin, an anti-parasitic, was administered to some patients across the globe, with seemingly positive effects. However, more studies show it has little to no effect when it comes to treating COVID-19. There’s also been an increase in calls to poison centers by people who are taking ivermectin intended for animals.

On one side, there are doctors who say ivermectin could help end the pandemic if used globally. On the other are public health officials who have reviewed the data and say the drug’s effectiveness against COVID-19 isn’t conclusive.

Here’s everything you need to know about ivermectin and its use for COVID-19.

What is ivermectin?

Ivermectin is an anti-parasitic medicine «that works by altering cellular channels,» said Dr. Soumi Eachempati, CEO of Cleared4 and former professor of surgery and public health at Weill Cornell Medical College. The drug inhibits some viruses from infecting cells, thus preventing the virus from spreading. Ivermectin is usually given to treat parasitic infections like lice and Strongyloides, according to Eachempati.

Scientists at pharmaceuticals giant Merck discovered ivermectin in 1975 and began to use it to treat scabies, river blindness and other parasitic diseases carried by worms and lice starting in 1981. It’s on the World Health Organization’s list of essential medicines for a basic health care system. More than 250 million people take the drug across the globe each year, and it’s effective for animals as well.

The drug is considered safe when taken in appropriate dosages. Side effects for the ivermectin vary depending on whether it’s taken orally to treat intestinal infections or topically for skin infections. Oral tablets can cause drowsiness, nausea, vomiting and, in very rare cases, an increase in heart rate and seizures. Side effects for the topical ivermectin can include skin rash and irritation, while dry skin and stinging pain are severe and rare.

Can ivermectin be used to cure COVID-19?

This is where things get complicated. Public health agencies, including the Federal Drug Administration, the National Institutes of Health and the World Health Organization, don’t suggest ivermectin’s use to treat COVID-19. They cite the lack of data from large, randomized trials confirming the drug’s effectiveness to treat the disease.

Doctors who cited multiple smaller studies and firsthand experience say otherwise. They claim ivermectin does work to prevent people from developing symptoms from COVID-19 and can shorten recovery time for those already infected.

What do the public health agencies say about ivermectin use for COVID-19 treatment?

The FDA said in March it hasn’t approved the use of ivermectin to treat COVID-19. It warned that large doses of the drug are «dangerous and can cause serious harm.» The agency also advised against human use of ivermectin produced for animals, such as cows and horses, as the doses aren’t the same and could contain ingredients intended only for animals.

window.CnetFunctions.logWithLabel(‘%c One Trust ‘, «Service loaded: script_twitterwidget with class optanon-category-5»);

A growing number of people have been taking ivermectin for animals as word’s spread on social media about its possible use against COVID-19. This has resulted in some people calling state poison centers after taking the drug, since the medication is intended for animals. On Aug. 20, the Mississippi State Department of Health sent out an alert regarding the number of calls its poison center received, with 70% related to the «ingestion of livestock or animal formulations of ivermectin purchased at livestock supply centers

In April, the FDA reaffirmed in a post on its website that ivermectin isn’t approved to treat COVID-19 nor has it been given emergency use authorization.

The NIH said in February there was insufficient data to «recommend either for or against the use of ivermectin for the treatment of COVID-19.» It did say lab tests found the drug stopped the reproduction of the SARS-CoV-2 virus that cause the disease. However, to be effective, the dosages would need to be «100-fold higher than those approved for use in humans.»

While some clinical studies showed ivermectin to have no benefit, the NIH said others saw a lower mortality rate among patients. However, those studies were incomplete or had methodological limitations such as small sample sizes or patients receiving additional medicine along with ivermectin, according to the NIH.

The WHO said in March the current evidence on the use of ivermectin for treatment of COVID-19 was «inconclusive.»

A doctor in Arkansas who prescribed the drug to patients is under investigation by the state medical board, according to a report from CNN. He reportedly gave ivermectin prescriptions to prisoners at the county jail where he was contracted to provide medical services.

Who says ivermectin is a treatment, and what information do they have?

Ivermectin’s potential use as a COVID-19 therapeutic made headway last December during a Senate Homeland Security Committee meeting called Focus on Early Treatment of COVID-19. Dr. Pierre Kory, a pulmonary and critical care specialist, testified about the drug’s usage for treatment of the disease.

«Ivermectin is highly safe, widely available, and low cost,» Kory said in the Senate meeting. «We now have data from over 20 well-designed clinical studies, 10 of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths. These data show that ivermectin is effectively a ‘miracle drug’ against COVID-19.»

During his testimony, Kory referred to a paper he authored — Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 — that was published in the May edition of the American Journal of Therapeutics.

The paper was also included in the Frontiers of Pharmacology journal in January but was then removed in March. Dr. Frederick Fenter, chief executive editor of the journal, said the paper was removed due to «strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.» Fender also said the authors promoted their own specific ivermectin-based treatment, which goes against editorial policies.

A study listed in Kory’s paper involved giving ivermectin to 234 uninfected health care workers in Argentina and found those who received the drug were far less likely to be diagnosed with COVID. For mildly ill patients, an Iraq study saw a quicker recovery time.

There are also studies that show otherwise. A clinical trial of 476 patients found ivermectin didn’t improve the recovery time in patients who had COVID-19. A review of 10 random clinical trials, with more than 1,000 participants, also didn’t find improvements with ivermectin. One Egyptian study claimed to show positive results, but it’s since been redacted over ethical concerns. Another study, of 1,500 patients, found that ivermectin had «no effect whatsoever.»

Merck, the company that discovered ivermectin, released a statement in February saying there was «no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies» and «no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease.» It also cited a lack of safety data from major studies.

Why is there controversy over ivermectin?

The debate about ivermectin’s usage to treat COVID-19 has gone from the hospital to social media, exacerbating the discourse as well as the vitriol. While those in support of the drug appear to want an end to the pandemic, their arguments in favor of ivermectin have become fodder for anti-vaxxers and conspiracy theorists.

Groups that have spread misinformation about COVID-19 throughout the pandemic latched onto ivermectin’s usage following Kory’s Senate testimony. Anti-vax groups on Telegram share misinformation about the vaccine while asking where they can buy the drug. Rumble, an alternative video platform to YouTube, has pages of videos falsely saying vaccines are ineffective while advising people to also take ivermectin.

Anti-vax posts and videos can also be found on YouTube, Facebook and Twitter, although the companies are attempting to take these posts down or make them harder to find.

Kory was a guest on the Dark Horse Podcast hosted by Bret Weinstein, a former professor at Evergreen State College, on June 1 to talk about ivermectin. That video was eventually demonetized on YouTube and Weinstein’s channel received a strike, which prevented him from posting content for one week and could lead to its removal if he receives two more strikes within 90 days.

YouTube says its actions on Weinstein’s videos were part of its policies.

«While we welcome open discussions of potential treatments and clinical trials related to COVID-19 on YouTube, based on guidance from the CDC, FDA and other local health authorities, we don’t currently allow content that recommends ivermectin as an effective treatment or prevention method for the virus,» said Ivy Choi, a YouTube spokesperson. «We craft our policies to prevent the risk of egregious real-world harm, and update them as official guidance evolves. We do allow exceptions to our policy about ivermectin, including content that also gives viewers the full context of the FDA’s current position

Because of YouTube’s decision, the controversy over ivermectin grew and became tied to what some claim to be «big tech censorship.»

What is required for ivermectin to get approved for COVID-19 treatment?

For the public health agencies, it’s going to come down to the results of large clinical studies being conducted around the world.

«In the UK, it was announced that ivermectin will be added to the Principle Trial, a large clinical study designed to assess potential COVID therapies for non-hospitalized therapies for patients at higher risk for severe disease,» said Dr. David Shafran, head of pediatrics at telehealth app K Health. «This should demonstrate more definitively the efficacy of ivermectin in early-stage COVID infections. Fingers crossed because it’s a cheap medication with a good safety profile. It would be great to add this to the armament of medication to fight COVID.»

The Oxford University Principle Trial has more than 5,000 participants and will give a three-day course of oral ivermectin treatment to individuals randomly and compare their results to individuals who will receive standard care.

In the US, the NIH is evaluating therapeutics for COVID-19 with its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol. ivermectin was added in phase three of ACTIV-6, which will test the effectiveness of repurposed drugs.

«The ACTIV prioritization group, trial team and trial oversight groups continuously track new data on any agent we are studying in our trials and evaluate that data for how it might influence our testing of that agent and the safety/well being of the participants in the trial,» said Dr. Sarah Dunsmore, a program director at the National Center for Advancing Translational Sciences that is part of the NIH.

What’s unclear is how long the whole process will take. The studies need time to be completed, and then the agencies will require additional time to come up with decisions based on the data.

Technologies

Apple and Google Broke Their Own Rules by Promoting ‘Nudify’ Apps, Report Says

A new report from the Tech Transparency Project found over 100 apps on app stores are designed to «undress people» from photos.

If you want an app you built to be downloadable from the Apple App Store or Google Play Store, it has to pass a slew of criteria, including safety standards. 

But a new report on Wednesday alleges that Apple and Google broke their own rules by promoting «nudify» apps that are outlawed in their app store policies.

The Tech Transparency Project, part of a nonprofit tech watchdog, first revealed in January that Apple and Google app stores had over 100 nudify or undressing apps. These are apps with the sole purpose of taking images of people, usually women, and editing them to appear to be that person without clothing, creating what’s called nonconsensual intimate imagery. Many of these apps use generative AI to create deepfakes. 

Apple removed some of the prohibited apps at the time. But many are still out there, as evidenced in a subsequent investigation.

In April, TTP found that Apple and Google still allowed users to search for a number of troubling keywords, including «nudify,» «undress» and «deepnude.» After a deep dive on the top 10 apps across both app stores, TTP found that 40% of the apps advertised themselves as able to «render women nude or scantily clad,» according to the report. 

The new report also found that Google and Apple actually promoted such apps in their stores, increasing their visibility, with Google in particular creating «a carousel of ads for some of the most sexually explicit apps encountered in the investigation.»

Read More: How to Keep Kids Safe Online? Europe Believes Its Age-Verification App Is the Answer

Apple and Google both have language in their policies that prohibits apps with «overtly sexual or pornographic material» (Apple) and «sexually suggestive poses in which the subject is nude, blurred or minimally clothed» (Google). And they’ve both enforced these policies in the past — particularly by going after porn apps. 

But Apple and Google make money from app developers by running advertising and taking a part of paid app subscriptions. Analytics firm AppMagic found that these «nudify» apps were downloaded 483 million times and made more than $122 million in lifetime revenue.

«This revenue stream may be why the two companies have been less than vigilant when it comes to nudify apps that violate their policies,» TTP writes.

After news broke this week, Apple told Bloomberg News that it removed 15 of the reported apps. Google confirmed it removed seven. Apple also said it blocked several of the search terms TTP flagged in its report. Apple and Google did not immediately respond to CNET’s requests for comment and any updates since Wednesday.

Nonconsensual graphically sexual content is a growing issue, due in part to AI. We saw in startling clarity how apps with AI can be used to make this illegal and abusive content at the beginning of the year, when Grok users made 1.4 million sexualized deepfakes over a nine-day period. 

Some US senators at the time called on Apple and Google to remove Grok from their app stores, but neither removed it. 

We learned this week that Apple privately reached out to Grok to express its concerns about its abusive AI capabilities and threatened to remove it. Grok is still available in the Apple and Google app stores and is still reportedly able to create abusive AI sexual images, despite the company saying otherwise.

Continue Reading

Technologies

OpenAI Has a New AI Model Built for Biology and Science

GPT-Rosalind is intended to help scientists streamline their research and drug discovery.

OpenAI’s latest AI model is built to do far more than offer cooking advice or create a spreadsheet. GPT-Rosalind, the company’s first model specifically built for life science, is meant to help scientists with drug discovery, biology and translational medicine. 

The model is named after Rosalind Franklin, whose research revealed the structure of DNA and formed the foundations for modern molecular biology. Scientific research relies heavily on data, and GPT-Rosalind is designed to help sort through it, while also helping reduce the time it takes to develop and get new drugs approved and out on the market. 

(Disclosure: Ziff Davis, CNET’s parent company, in 2025 filed a lawsuit against OpenAI, alleging it infringed Ziff Davis copyrights in training and operating its AI systems.)

It can take 10 to 15 years for a new drug to be developed and approved in the US, OpenAI said in a blog post Thursday. GPT-Rosalind is intended to improve the selection of research targets and create stronger hypotheses for higher-quality experiments. 

The model has been tested on topics such as its understanding of organic chemistry, proteins and genetics. Researchers can use it to find relevant scientific literature for their work or design experiments.

This isn’t the first time an AI model has been developed with medical advancements in mind. Google DeepMind has developed many AI models for scientific research, such as AlphaFold, which earned its creators a share of the 2024 Nobel Prize in Chemistry.

«For me, the best use case for AI was to improve human health and accelerate scientific discovery,» Google DeepMind CEO Demis Hassabis said in a recent interview. Anthropic introduced Claude for Life Sciences in January with the same purpose. 

Some scientists have expressed concerns in the past about how quickly AI has infiltrated the science space and have warned of vulnerabilities, potential misuse and issues with data representation.

OpenAI said GPT-Rosalind has safeguards to protect it from misuse — like the creation of a biological weapon — and has teamed up with various biotechnology, pharmaceutical and life sciences technology organizations to support research and scientific discovery.

Sean Bruich, senior vice president of artificial intelligence and data at the biopharmaceutical company Amgen, said in a statement that scientific work requires precision: «Our unique collaboration with OpenAI enables us to apply their most advanced capabilities and tools in new and innovative ways with the potential to accelerate how we deliver medicines to patients.»

GPT-Rosalind is available only through OpenAI’s trusted-access system as a research preview. 

Continue Reading

Technologies

Was This Game Just On Sale? Steam May Show Price Shifts Over the Past 30 Days

A price tracker would make it easy to tell if you’re getting a good deal on a game or not.

Steam is the largest video game platform with more than 129,000 games and counting. With so many games and the company offering frequent sales, it’s hard to keep track of whether a game has is at its lowest price or if its been discounted further in the past, but that may change. 

Lines of code found in the Steam platform seemingly refer to the recent price history for a game, according to a post on Wednesday from the X account for the Half-Life fan site Lambda Generation. The code was discovered by data miner SigaTbh, who found it on SteamDB, a database and tracking site for the gaming platform. While price history is already a feature on Steam in the European Union, this update could be the first sign that it will become the norm for the platform over in the U.S. 

In the image posted by Lambda Generation, there are six lines of code referencing «Price_History» and each line reflects a certain detail that could show up on a game’s page to give some context about its price. The price history would show the normal price for the game, the current price, whether the current price is a 30-day low or if the game was at a lower cost sometime within the past 30 days. 

Valve didn’t immediately respond to a request for confirmation about the new feature. 

Back in 2023, Valve added the price history feature to Steam in the EU as part of the Omnibus Directive. The directive is a series of rules set by the EU focusing on consumer protection. Companies with digital storefronts were required to institute a price tracker on their platforms to display the lowest price of an item for the past 30 days. Even though the Omnibus Directive is in full effect, however, it’s not available in every member state of the EU, as individual countries have to adopt the directive. 

Certain rules in the EU that require certain changes to be made to a product or service eventually find their way to the U.S. Apple was forced to add USB-C to its iPhone 15 lineup due to EU legislation requiring standardization of charging ports. 

It’s unclear why Valve would make the move to add a price tracker to Steam in the U.S. The company is reportedly working on an AI bot for the platform dubbed «SteamGPT,» and the price history could be part of its features. 

Continue Reading

Trending

Copyright © Verum World Media